Encelto (revakinagene taroretcel-lwey)
Summary
BCBS Mississippi has added a new policy stating that Encelto (revakinagene taroretcel-lwey), a gene therapy for macular telangiectasia type 2, is considered not medically necessary and will not be covered. Claims for this treatment and its administration will be denied unless approved through prior authorization review.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.